Trials / Terminated
TerminatedNCT06419478
Postoperative Symptoms in Chinese Liver Cancer Patients: Network Analysis
Exploring Early Postoperative Core Symptoms in Chinese Patients With Primary Liver Cancer: a Cross-sectional and Longitudinal Network Analysis
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 249 (actual)
- Sponsor
- Mengmeng Yuan · Academic / Other
- Sex
- All
- Age
- 40 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Patients with primary liver cancer (PLC) experience a range of symptoms in the early postoperative period. Symptoms include cancer-related symptoms and adverse effects of treatment. Exploring the core symptoms and their dynamics in the early post-hepatectomy patients may help provide better symptom management programs. The purpose of this study was to identify the core symptoms in early post-hepatectomy patients and to explore the trajectory of their dynamics. During the period from March 2021 to September 2022, a total of 281 patients diagnosed with PLC and undergoing radical curative surgery were recruited from the hepatobiliary surgery departments of two hospitals in Eastern China, among whom 249 individuals (88.60%) agreed to participate in the study. A comprehensive symptom assessment was administered to the patients 1-2 days after surgery (T1) and 1-2 days before discharge (T2). Network analysis was used to identify core symptoms in early post-hepatectomy patients based on symptom severity.
Conditions
- Patients With Primary Liver Cancer (PLC) Undergoing Curative Surgical Procedures
- Importance of Identifying Core Symptoms for Improving Symptom Management in PLC Patients
- Application of Network Analysis as a Crucial Component of Cancer Care
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | postoperative symptoms | Observational study, focusing solely on symptom surveys of patients. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2022-08-31
- Completion
- 2022-09-01
- First posted
- 2024-05-17
- Last updated
- 2024-05-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06419478. Inclusion in this directory is not an endorsement.